Viewing Study NCT06796803


Ignite Creation Date: 2025-12-24 @ 7:13 PM
Ignite Modification Date: 2025-12-30 @ 2:48 AM
Study NCT ID: NCT06796803
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-02-10
First Post: 2025-01-22
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
Sponsor: Shanghai Zhongshan Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module